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Abstract
Background: While neurosphere- as well as xenograft tumor-initiating cells have been identified in gliomas, the
resemblance between glioma cells and neural stem/progenitor cells as well as the prognostic value of stem/progenitor cell
marker expression in glioma are poorly clarified.
Methodology/Principal Findings: Viable glioma cells were characterized for surface marker expression along the glial
genesis hierarchy. Six low-grade and 17 high-grade glioma specimens were flow-cytometrically analyzed for markers
characteristics of stem cells (CD133); glial progenitors (PDGFRa, A2B5, O4, and CD44); and late oligodendrocyte progenitors
(O1). In parallel, the expression of glial fibrillary acidic protein (GFAP), synaptophysin and neuron-specific enolase (NSE) was
immunohistochemically analyzed in fixed tissue specimens. Irrespective of the grade and morphological diagnosis of
gliomas, glioma cells concomitantly expressed PDGFRa, A2B5, O4, CD44 and GFAP. In contrast, O1 was weakly expressed in
all low-grade and the majority of high-grade glioma specimens analyzed. Co-expression of neuronal markers was observed
in all high-grade, but not low-grade, glioma specimens analyzed. The rare CD133 expressing cells in low-grade glioma
specimens typically co-expressed vessel endothelial marker CD31. In contrast, distinct CD133 expression profiles in up to
90% of CD45-negative glioma cells were observed in 12 of the 17 high-grade glioma specimens and the majority of these
CD133 expressing cells were CD31 negative. The CD133 expression correlates inversely with length of patient survival.
Surprisingly, cytogenetic analysis showed that gliomas contained normal and abnormal cell karyotypes with hitherto
indistinguishable phenotype.
Conclusions/Significance: This study constitutes an important step towards clarification of lineage commitment and
differentiation blockage of glioma cells. Our data suggest that glioma cells may resemble expansion of glial lineage
progenitor cells with compromised differentiation capacity downstream of A2B5 and O4 expression. The concurrent
expression of neuronal markers demonstrates that high-grade glioma cells are endowed with multi-lineage differentiation
potential in vivo. Importantly, enhanced CD133 expression marks a poor prognosis in gliomas.
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Introduction
Gliomas, the most common primary tumors in the adult central
nervous system, are currently classified according to their
morphological features, into low- and high-grade glioma. Cells
of low-grade (I and II) gliomas are well differentiated with clear
histological similarity to astrocyte or oligodendrocyte lineage.
High-grade (III and IV) gliomas are more anaplastic, with features
resembling immature astrocytes, oligodendrocytes or a mixture of
both types. Low-grade gliomas are frequently diagnosed in
relatively young patients and many of these eventually develop
into anaplastic gliomas which subsequently progress to the so-
called secondary glioblastoma (GBM). In contrast, the GBM in
older patients are mostly diagnosed as de novo without any clinically
detectable history. It is unclear whether the early stages of de novo
GBM development resemble low-grade gliomas. Although previ-
ous studies suggested glioma expression of oligodendrocyte
progenitor cell antigen NG2 and PDGFRa, and transcription
factor Olig1/2 [1–3], the lineage commitment and the stage of
differentiation blockage of glioma cells are not clarified [4].
For decades, the median survival of high-grade gliomas has
not been significantly improved [4]. In efforts to identify crucial
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1936cellular and molecular targets for glioma treatment, recent
studies have indicated that all grades of gliomas contain putative
tumor stem cells, which can be CD133
+ or CD133
2 [5,6]. These
cells are endowed with self-renewal and multi-lineage differen-
tiation capacity in neurosphere-forming assay, a surrogate assay
for neural stem cells. Particularly, CD133
+ putative GBM stem
cells were capable of xenograft GBM initiation where the
CD133
2 GBM cells from the same patients failed to do so [7–9].
Compared with normal neural stem/progenitor cells, glioma
derived cells showed an enhanced and more aggressive self-
renewal capacity [9]. Thus, neurosphere-forming glioma cells,
which may or may not be CD133
+, are likely to be the crucial
targets for successful treatment. However, neurosphere-forming
capacity is an in vitro growth factor dependent feature common to
neural stem cells as well as progenitor cells [10]; it is also likely
that cells normally not endowed with such capacity can gain
neurosphere-forming capacity due to transformation mecha-
nisms. In fact, glial lineage restricted progenitor cells can in vitro
be reprogrammed to acquire multi-lineage differentiation capac-
ity in an environmental cue dependent manner [11]. It has been
unclear whether glioma cells in vivo are endowed with a multi-
lineage differentiation potential. Similarly, xeno-transplantation
may only assess those tumor cells capable of adapting to growth
in a mouse environment [12,13]. It is therefore controversial
whether neurosphere- or xenograft tumor- initiating glioma cells
represent the authentic glioma stem cells, from which gliomas
originate [14].
In analogy with the well characterized hematopoiesis hierarchy,
mature neural cells are derived from the neural stem cells via
multiple progressively committed/differentiated intermediate pro-
genitor cells [15]. The differentiation stages along the hematopoi-
etic hierarchy of primitive hematopoietic cells and leukemic cells
can, to a significant extent, be inferred from surface marker
expression in combination with functional analysis [16]. Similar
strategies have been applied to identify the primitive neural cells.
For example, cells with CD133
+CD34
2CD45
2CD24
2 phenotype
represent the neural stem/progenitor cells from embryonic human
brain tissues [17]. Neuronal lineage restricted precursors can be
isolated via E-NCAM expression [18,19]. Along the glial lineage,
the neural stem cell derived immediate progeny are likely the
A2B5 expressing glial-restricted precursor (GRP), which are
capable of generating oligodendrocytes, type-2 astrocytes and
type-1 astrocytes [20,21]. Other types of glial lineage progenitor
cells, likely downstream to GRP, have also been identified via
A2B5 expression [20–27]. Although the exact in vivo relationship
between these A2B5 expressing glial precursors has been
challenging to establish, in vitro studies have demonstrated that
GRP can generate oligodendrocyte/type-2 astrocyte progenitor
(O-2A) cells and type-1 astrocyte-restricted progenitor (ARP)
[21,28]. The O-2A progenitor cells, which are characterized by
cell surface expression of platelet-derived growth factor receptor-a
(PDGFRa), A2B5 and O4, can account for 4% of the adult human
white matter cells [22,25,26]. Via early and late oligodendrocyte
progenitors, which gradually lose PDGFRa, A2B5 and O4
expression and gain O1 expression in pre-myelinating oligoden-
drocytes, O-2A progenitor cells give rise to oligodendrocytes
[21,27,29]. But O-2A progenitor cells can in vitro also give rise to
type-2 astrocytes in a growth factor cue dependent manner [26].
Depending on the utility of growth factor combinations, O-2A
progenitor cells can also be reprogrammed to acquire neuro-
sphere-forming and neuronal lineage differentiation capacities
[11]. The ARPs also express A2B5, but not PDGFRa and O4
[22–24,29]. Human ARPs were also demonstrated to express
CD44 [28,30].
As demonstrated in previous studies, although gene expression
of cancer cells reflects genetic and epigenetic alterations, a
considerable fraction of this gene expression can nevertheless be
characteristic of the non-transformed cell-of-origin. This principle
has been applied to distinguish between leukemias originating
from either stem cells or from progenitor cells by characterization
of cancer initiating capacity and cancer-characteristic genetic
mutations in these cell fractions [31,32]. In this study, we
characterized freshly isolated low-grade and high-grade glioma
cells for expression of surface markers characteristic of the glial
lineage differentiation hierarchy and analyzed the expression of
these markers in relation to patient survival. We also studied the
glioma cell multi-lineage differentiation potential in vivo by
assessing GFAP and NSE/synaptophysin expression in the
corresponding formaldehyde fixed specimens.
Materials and Methods
Tumor specimens, cell processing and flow cytometric
analysis
Glioma biopsies of fresh tumor tissue were obtained from
patients operated at the Clinic of Neurosurgery, Lund University
Hospital, Sweden. Formaldehyde-fixed, paraffin embedded tissue
blocks derived from the same surgical excision biopsies were
obtained from the Department of Pathology, Lund University
Hospital. Patient survival data were obtained from the Swedish
National Register of Population (National Board of Health and
Welfare). Permission for using these materials was obtained from
The Regional Ethical Review Board in Lund, and written
informed consent was obtained from patients.
For preparing viable glioma cells, freshly obtained specimen
were cut finely into small pieces, treated in IMDM with 0.5 mg/
ml collagenase (Sigma) and 25 mg/ml DNAse (Sigma) at 37uC for
40 minutes. Red cells were lysed with NH4Cl; the resulting cells
were washed in PBS containing 2% FCS. For flow-cytometry
analysis, these cells were either used directly or resuspended in
freezing medium containing 10% DMSO and 90% FCS for
storage in liquid nitrogen. About 5 to 10610
6 of the freshly
isolated or thawed cells were first incubated with non-specific
blocking mouse IgG1 at 50 mg/ml (clone MOPC 21, Sigma) at
4uC for 20 minutes. Subsequently, about 5610
5 cells were stained
with allophycocyanin (APC)-conjugated anti-CD45 (clone 2D1),
anti-CD31 (clone AC114.5) monoclonal antibodies (mAb) in
combination with one of the fluorescein isothiocyanate or
phycoerythrin (PE)-conjugated mAbs against PDGFRa (clone
aR1), CD44 (clone G44-26), CD24 (clone ML5), EGFR (clone
EGFR1) or CD133 (clone AC133), or the isotype-matched control
mAbs, at saturating concentrations at 4uC for 15 minutes.
Subsequently, cells were washed once with PBS and resuspended
in 500 ml PBS supplemented with 2% FCS and 1.0 mg/ml 7-
aminoactinomycin D (7-AAD, Sigma). The A2B5, O4, and O1
staining were detected using PE-conjugated rat-anti-mouse-IgM
(clone Rat(LOU)IgG2a) and a staining omitting the unconjugated
primary mAb served as control. The multiparameter flow
cytometric analysis was performed in a FACScalibur. At least 50
000 events were counted and cell surface expression was analyzed
in 7-AAD negatively stained living cells using the Cellquest or
Flowjo program. PE-conjugated anti-CD133 and APC-conjugated
anti-CD31 mAbs were purchased from Miltenyi Biotec (Bergisch
Gladbach, Germany) and unconjugated anti-A2B5 (MAB312R),
O4 (MAB345), and O1 mAb (MAB1327) from Chemicon Europe,
Ltd. (Hampshire, UK). All other mAbs were purchased from BD
Biosciences Immunocytometry Systems. The flow-cytometry
analysis was performed at least twice for most of the specimens
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analyzed with two batches of anti-CD133 mAb with comparable
data.
Karyotype analysis of short-term cultured glioma cells
Freshly isolated or thawed glioma cells were cultured in
DMDM/F12 medium supplemented with 2% fetal calf serum,
basic fibroblast growth factor (20 ng/ml), platelet derived growth
factor-AA (20 ng/ml), sonic hedgehoge (2 ng/ml) and 16N2.
Chromosome banding analysis was performed between passage
3 to 4 by standard methods.
Immunohistochemistry analysis
Sections of five-mm thickness were mounted on capillary glass
slides (DAKO ChemMate Capillary Gap Microscope Slides,
75 mm, DAKO Sweden AB). All sections were microwave pre-
treated in 10 mM citrate buffer pH 6.0 for 15 minutes at 800 W
in order to achieve antigen retrieval. An automated immunostai-
ner (TechMateTM 500 Plus, DAKO Sweden AB) was used for the
staining procedure using DAKO ChemMate Kit Peroxidase/3-
39diaminobenzidine. Primary antibodies used were GFAP
(DAKO, polyclonal, 1:5000 dilution), NSE (Zymed, clone NSE-
1G4, 1:1500 dilution) and synaptophysin (DAKO, polyclonal,
Figure 1. Low-grade glioma cells concurrently express multiple cell surface markers characteristic of adult human glial progenitors.
Dot-plot profiles of glial progenitor cell surface markers and CD133 expression on low-grade glioma cells from two representative patients (#1 (A)
and #4 (B)) are shown. Freshly isolated glioma cells were simultaneously stained with the indicated antibodies. The hematopoietic cells were
distinguished with anti-CD45 staining. The numbers in each quadrate represent the percentages of the cells stained positively or negatively by the
respective antibodies.
doi:10.1371/journal.pone.0001936.g001
Table 1. Expression of neural stem cell and glial progenitor surface markers in low- and high-grade glioma specimens analyzed.
Patient ID (Age/gender) Pathological diagnosis Cells expressing indicated markers (%)
PDGFRa A2B5 O4 O1 CD44 CD24 EGFR CD133
Low-grade glioma
1 (45/F) oligoastrocytoma (II) 89 97 99 13 97 99 UD 2.5
2 (6/M) pilocytic astrocytoma 100 ND ND ND 100 UD UD UD
3 (7/F) pilocytic astrocytoma 78 59 96 ND 89 UD UD 15
4 (36/M) astrocytoma (II) 71 100 100 11 78 78 71 8
5 (52/M) astrocytoma (II) 75 79 84 43 76 30 28 8
6 (60/M) astrocytoma (II) UD 100 100 29 100 44 UD UD
High-grade glioma
7 (47/M) GBM UD ND ND ND 100 ND UD UD
8 (31/M) anaplastic oligodendroglioma UD 100 100 18 61 UD UD UD
9 (62/M) GBM UD 50 UD ND 100 UD 30 UD
10 (8/M) anaplastic astrocytoma 32 43 45 32 32 UD UD UD
11 (66/M) GBM UD 46 17 13 100 UD UD UD
12 (36/M) GBM 45 64 58 ND 26 12 27 10
13 (70/F) GBM UD 79 19 ND 96 9 UD 72
14 (47/F) GBM 63 77 90 ND 92 UD 92 77
15* (38/M) GBM 96 95 97 66 90 93 80 29
16* (49/M) oligoastrocytoma III 98 96 96 64 99 98 UD 22
17 (65/M) GBM 69 100 100 26 85 24 96 90
18 (51/F) GBM 30 63 74 ND 87 UD 83 16
19 (63/F) GBM UD ND ND ND 83 ND 73 70
20 (67/M) GBM 50 ND ND ND 100 UD 100 50
21 (58/F) GBM 38 74 79 46 88 UD 50 53
22 (61/F) anaplastic oligodendroglioma 100 100 100 ND 100 100 100 54
23 (55/F) GBM 38 85 94 83 81 66 72 47
Other types of brain tumors
24 (45/M) PNET UD UD UD UD UD UD UD 94
25 (62/M)24 (45/M) anaplastic ependymoma UD 25 UD UD 100 UD 100 15
Freshly prepared or thawed glioma cells were first incubated with non-specific mouse IgG1 mAb, cells were subsequently incubated with APC conjugated anti-CD45
mAb in combination with FITC conjugated anti-CD44, or anti-CD24 mAbs or PE conjugated anti-PDGFRa, anti-EGFR, anti-CD133 mAbs. For A2B5 and O4 staining, cells
were incubated with unconjugated A2B5 or O4 mAb respectively and subsequently stained with PE conjugated rat anti-mouse IgM. Cells negatively stained with 7-AAD
were analyzed for cell surface marker expression. Data shown are the percentages of CD45 negative cells positively stained for indicated cell surface markers.
*: secondary GBM. UD: undetectable; ND: not done. PNET: primitive neuroectodermal tumor.
doi:10.1371/journal.pone.0001936.t001
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proportion of positively stained versus total cell numbers and the
extent of staining intensity. These two variables generally co-vary
between samples. The staining was judged as either markedly
positive (++), low-moderately positive (+) or negative (2).
Results
We have analyzed the expression of PDGFRa, A2B5, O4 and
CD44 as surface markers for glial precursor cells [17,20–24,27–
30], and CD133 for stem cells [7,17] on freshly prepared glioma
cells using flow cytometry. In addition, we analyzed the expression
of EGFR, which is expressed in immature astrocytes and is
critically important for astrocyte development [33]. EGFR is also
frequently overexpressed in high-grade glioma cells [34]. Six low-
grade and 17 high-grade glioma specimens were analyzed. As
shown by representative dot-plot profiles for low-grade glioma
specimens (Figure 1), intermingled cells of hematopoietic origin
can be distinguished via their CD45 expression. PDGFRa, A2B5,
O4, and CD44 were found to be expressed in nearly all CD45
negative cells. The concomitant expression of these progenitor cell
markers was observed in nearly all low-grade glioma specimens
analyzed (Table 1). These data, combined with the homogenous
GFAP staining and the absence of NSE/synaptophysin staining
(Table 2 and Figure 2), suggest that low-grade glioma cells are
reminiscent of glial-progenitor cells. In 4 out of 6 low-grade glioma
specimens, CD133 expression was observed at lower frequencies,
but these CD133
+ cells are predominantly of blood vessel
endothelial origin (see below). The expression of EGFR was
found in specimens from 2 of the 6 low-grade gliomas. We also
analyzed the expression of CD24. Absence of CD24 expression in
combination with positive staining on CD133, or PNA or
ABCG2/Bcrp1 was used to enrich primitive neural cells with
‘‘stem cell-like’’ properties [17,35–38]. CD24 expression was
detected in 4 out of 6 low-grade gliomas.
As in low-grade glioma cells, high-grade glioma cells analyzed in
this study maintained the expression profiles for PDGFRa,A 2 B 5 ,
O4and CD44( Table1and Figure 3).In allthesehigh-grade glioma
cases, GFAP expression was detected with inter- as well as intra-
glioma variation (Table 2 and Figure 2). The expression of CD24
was observed in 7 of 16 high-grade gliomas analyzed. In striking
contrast to the low-grade glioma cells, distinct cell populations with
high intensity of CD133 expression (ranging from 22 to 90% of the
CD45
2 cell fraction) was detected in 12 of the 17 high-grade glioma
specimens. In addition, EGFR over-expression was detected in 11 of
the17high-gradegliomaspecimensanalyzed.Ofnote,nodetectable
difference in cell surface marker expression profile was observed
between the secondary (patients ID 15 and 16) and de novo GBM
specimens analyzed (Table 1).
As gliomas, particularly the high-grade gliomas, are highly
vascularized, newly formed blood vessel endothelial cells may also
express CD133 [39]. To ascertain the glioma origin of the
CD133
+ cell fraction in our low-grade and high-grade glioma
specimens, we subsequently performed CD133 expression analysis
in combination with CD45 and CD31 staining. By doing so, it is
possible to distinguish glioma cells from both hematopoietic cells
(via CD45 expression) and tumor blood vessel endothelial cells (via
CD31 expression) [40]. As shown in Figure 4, a small population
of CD45
2, but CD133
+ cells can be detected in low-grade glioma
specimens. Relatively higher frequencies of such cells were found
in GBM specimens. However, such CD45
2CD133
+ cells were
predominantly CD31
+ in low-grade glioma specimens (ranging
from 0.3 to 7% of the total living cells, n=4). This indicates that
CD133
+ cells, if present in low-grade gliomas, are predominantly
derived from newly formed blood vessel endothelial cells, and not
from the glioma cells. In GBM specimens, the majority of CD133
+
cells were of glioma origin, although CD31
+CD133
+ cells (ranging
from 0.5 to 10% of the total living cells, n=9) were also found.
In agreement with previous studies demonstrating glioma
expression of oligodendrocyte progenitor cell transcription factor
Olig1/2and surfaceantigen NG2 [1–3],the concomitant expression
of A2B5 (a marker for multiple types of progenitor cells in glial
lineage [20–27,41]), PDGFRa (a marker for early oligodendrocyte
progenitor cells at O-2A stage [22,25,26,42–44]) and O4 (a marker
for late oligodendrocyte progenitor cells [29]) suggests that glioma
cells, irrespective of their morphological characteristics, are
committed to the oligodendrocyte lineage. To further characterize
the differentiation stages along the oligodendrocyte lineage down-
streamof theA2B5expressing glialprogenitor celllevel,we analyzed
the expression of O1, a marker for pre-myelinating oligodendrocytes
[29]. In contrast to the high level A2B5 and O4 expression, the
frequency of O1
+ cells were significantly diminished in all low-grade
andthemajorityofGBMspecimensanalyzed(Table1andFigure5).
The expression of GFAP and these oligodendrocyte progenitor
surface markers suggests that along the oligodendrocyte lineage
differentiation hierarchy, A2B5
+/PDGFRa
+ glioma cells were
Table 2. Co-expression of neuronal and glial markers in high-
grade glioma cells
Patient ID GFAP NSE
1 (45/F) ++ -
2 (6/M) ++ -
3 (7/F) ++ -
4 (36/M) ++ -
5 (52/M) ++ -
6 (60/M) ++ -
7 (47/M) +++ +
8 (31/M) ++ ++
9 (62/M) +++ ++
10 (8/M) +++ +
11 (66/M) +++ ++
12 (36/M) +++ +
13 (70/F) ++ ++
14 (47/F) +++ +
15 (38/M) +++ +
16 (49/M) +++ +
17 (65/M) ++ ++
18 (51/F) ++ +
19 (63/F) +++ +
20 (67/M) +++ ++
21 (60/M) +++ +
22 (61/F) ++ +
23 (55/F) +++ +
24 (45/M) ++
25 (62/M) ++ -
The GFAP and NSE staining was performed in the fixed glioma specimens from
the same surgical procedures as those used for generating viable cells. The
staining was semi-quantitatively evaluated. +++: markedly positive staining; ++:
moderately positive staining; +: low positive; 2: no positive staining in the
tumor.
doi:10.1371/journal.pone.0001936.t002
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upstream of the O1 stage.
To study glioma cell differentiation potential along neuronal
lineage, we performed an immunohistochemical staining for pan-
neuronal marker NSE and synaptophysin expression in archival
specimens (Table 2 and Figure 2). In low-grade gliomas, no obvious
expression of NSE and synaptophysin was detected, but the cells
homogeneously expressed GFAP (Table 2 and Figure 2). We were
unable to ascertain whether the few cells weakly stained for NSE
were the intermingled normal neuronal cells or the glioma cells
(Figure 2, upper panel). In high-grade glioma cells, a regional NSE
expression was clear in all cases analyzed (Table 2 and Figure 2),
although both region-dependent and homogeneous expression
patterns were detected. Synaptophysin positivity was detected in 7
high-grade gliomas. These data, in combination with the expression
of GFAP and multiple oligodendrocyte lineage progenitor surface
markers (Tables 1 and 2, Figures 1, 2 and 3), suggest that compared
to low-grade glioma cells, high-grade glioma cells maintain glial
progenitor-like features, but additionally exhibit enhanced CD133
expression as well as neuronal differentiation potential.
Transformed glial progenitor-like cells can provide a niche
environment recruiting normal stem cells or progenitor cells into
the tumor mass [45]. To investigate whether freshly isolated glioma
cells studied here indeed contained transformed cells, karyotype
analysis was performed in short-term cultured glioma cells (Table 3).
We only observed normal karyotype for cells derived from patients 3
and 8. Abnormal karyotypes were observed from cells derived from
patients 4, 12, 13, 14, 17, 18 and 20. Of note, cultures derived from
low-grade glioma patient 4 and high-grade glioma patient 12
contained about 40% of the cells with a normal karyotype,
contrasting the nearly homogenous phenotype between all cells
(Figures 1, 3); but cultures derived from high-grade glioma patients
13, 14, 17, 18 and 20 predominantly contained cells with abnormal
karyotypes. In addition, fresh cells from patients 14 and 20 formed
xenograft glioma following subcutaneous injection into SCID mice
[46]. Thus, the analyzed glioma cells did contain neoplastic cells and
the karyotype normal and abnormal glioma cells showed hitherto
indistinguishable phenotype.
Finally, we investigated whether the glial progenitor or stem cell
markers expressed on glioma cells could serve as prognostic
Figure 2. Neuronal marker expression was not detected in low-grade gliomas, but in high-grade gliomas. Staining patterns of GFAP
and NSE expression from representative low-glioma (patient ID: #2) and high-grade glioma ((patient ID: #12 and #19) are shown. Original
magnification: 6100
doi:10.1371/journal.pone.0001936.g002
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PLoS ONE | www.plosone.org 6 April 2008 | Volume 3 | Issue 4 | e1936Figure 3. Maintenance of glial progenitor-like phenotype, but enhanced CD133 expression in high-grade gliomas. In addition to multiple
glial progenitor cell markers, a high proportion of glioma cells co-expressing CD133 was detected in most of the high-grade glioma specimens. Dot-plot
profiles of glial progenitor cell surface markers and CD133 expression on high-grade glioma cells from representative patients (#14 (A) and #22 (B)) are
shown. Freshly isolated glioma cells were simultaneously stained with the indicated antibodies. The hematopoietic cells were distinguished with anti-
CD45 staining. The numbers in each quadrate represent the percentages of the cells stained positively or negatively by the respective antibodies.
doi:10.1371/journal.pone.0001936.g003
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PLoS ONE | www.plosone.org 7 April 2008 | Volume 3 | Issue 4 | e1936Figure 4. Vessel or glioma origin of CD133 expressing cells. In contrast to high-grade glioma specimens, CD133 expressing cells detected in
low-grade glioma specimens are predominantly derived from blood vessel endothelial cells. Dot-plot profiles of CD133 expression versus CD45 and/
or CD31 expression of cells from glioma specimens of indicated patients are shown. The numbers in each quadrate represent the percentages of the
cells stained positively or negatively by the respective antibodies.
doi:10.1371/journal.pone.0001936.g004
CD133 Marks Poor Survival
PLoS ONE | www.plosone.org 8 April 2008 | Volume 3 | Issue 4 | e1936markers for patient survival. Glioblastoma patients receiving
immune therapy and patients with pilocytic astrocytoma or
ependymoma, were excluded from the prognosis analysis. We
divided all analyzed grade II to IV glioma patients into a CD133
+
low group (CD133
+ cells less than 30%) and a CD133
+ high group
(CD133
+ cells higher than 30%). The median survival time in the
CD133
+ high group was 5.069.2 months (n=9) compared to
more than 22.0617.3 months (n=10) in the CD133
+ low group
(P=0.026, t test; Figure 6). Thus, CD133 expression inversely
correlates with glioma patient survival time.
Discussion
In this study, we investigated the expression of multiple cell
surface markers characteristic of glial genesis hierarchy in freshly
isolated viable glioma cells as well as the expression of GFAP, NSE
and synaptophysin in the fixed specimens from a cohort of low-
grade and high-grade glioma patients. Our data show that nearly
all low-grade glioma cells from the analyzed cases concomitantly
express multiple cell surface markers for glial progenitor cells, such
as PDGFRa, A2B5, O4, and CD44. The expression of these glial
progenitor markers is maintained in the high-grade gliomas
analyzed. GFAP expression was detected, as anticipated, in all
low- and high-grade gliomas analyzed, but the expression of NSE
and synaptophysin was only detected in high-grade gliomas. Co-
staining of CD31 suggests that the rare CD133 expressing cells in
low-grade gliomas are predominantly of vessel endothelial origin.
In more than 50% of the high-grade glioma cases, distinct CD133
expression was detected in cells concomitantly expressing multiple
glial progenitor markers. Thus, low-grade glioma cells may
resemble the expansion of A2B5
+ glial progenitor-like cells; high-
grade gliomas, in addition to the expansion of A2B5
+ glial
Figure 5. Glioma cells are compromised in downstream differentiation at the O4 stage. Glioma cells were stained with APC conjugated
anti-CD45 and anti-CD31 mAbs in combination with staining for A2B5, or O4 or O1. Data shown are the ratio of the percentages between O4
+/
CD45
2CD31
2 and A2B5
+/CD45
2CD31
2 phenotype or between O1
+/CD45
2CD31
2 and A2B5
+/CD45
2CD31
2 phenotype in each patient. The
ependymoma patient was not included in this analysis.
doi:10.1371/journal.pone.0001936.g005
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+ putative glioma
stem cells that concomitantly express multiple surface markers of
glial progenitor cells. Irrespective of CD133 expression, high-
grade glioma cells are endowed with multi-lineage differentiation
potential in vivo. Importantly, CD133 expression negatively
correlated with the glioma patient survival time.
Conserved mechanisms across organ development/homeostasis
and tumorigenesis have been demonstrated in many types of
human cancers [47]. It is likely that gliomas may originate from the
primitive cells along the postnatal glial genesis hierarchy. In fact,
glial progenitor cells were demonstrated to be more susceptible to
oncogene transformation compared to mature astrocytes [48].
Glial genesis originates from neural stem cells via multiple types of
intermediate glial precursors [49]. In adult human CNS, putative
neural stem cells have been identified in restricted brain regions
[50]. In contrast, A2B5 and PDGFRa expressing O-2Aprogenitors
are relatively abundant throughout the CNS [24,25,41,51–53].
The aforementioned A2B5
+O4
2PDGFRa
2 GRPs and
A2B5
+O4
2PDGFRa
2CD44
+ ARPs may also exist. In addition
to well-established PDGFRa expression, we identified that the
majority of low-grade astrocytomas and high-grade gliomas
concomitantly express multiple markers of glial progenitor cells
such as A2B5 and O4. Our findings seem not consistent with
previous reports that astrocytomas could be divided into A2B5
+
and A2B5
2 lineages [54,55]. This discrepancy is likely caused by
the fact that the eiptopes recognized by the A2B5, O4 and O1
antibodies are not well maintained in formalin fixed, paraffin
embedded specimens, and our studies were performed in living
glioma cells. It is unlikely that the co-expression of these cell surface
markers is a consequence of a cell type dependent/independent
program inherent to all glioma cells, rather it reflects the
differentiation stage(s) common to normal glial genesis hierarchy
and glioma cells. In line with previous reports identifying
oligodendroglial lineage markers such as Olig2 or NG2/PDGFRa
as universal markers in diffuse gliomas [1–3], our study
demonstrates the shared pattern of concomitant expression of
multiple surface markers between glioma cells and oligodendrocyte
progenitor cells, which suggests that most of the morphologically
diagnosed astrocytoma and GBM are endowed with oligodendro-
cyte lineage differentiation potential. The data of weak O1
expression, but homogenous GFAP expression, indicate that these
cells are likely blocked at differentiation pathways between O4 and
O1 stages in oligodendrocyte lineage or at hitherto unidentified
stages towards type-2 astrocytes [20,21,28].
The expression of CD44 identifies the ARPs [28] and nearly all
gliomas express this marker. This CD44 expression does not
necessarily contradict the oligodendrocyte lineage commitment of
A2B5
+PDGFRa
+O4
+ glioma cells which exhibited a concomitant
GFAP expression, because a misexpression of CD44 can result in
expansion of oligodendrocyte progenitor cells with impaired
maturation and concomitant gain of GFAP expression [28].
However, it cannot be excluded that A2B5
+CD44
+GFAP
+ glioma
cells without detectable PDGFRa and O4 expression (e.g.: case
#9, Table 1) actually represent the expansion of ARP-like cells.
Previous neurosphere culture-based studies have demonstrated
that sphere-forming glioma cells are capable of multi-lineage
differentiation [8,9,56,57]. A potential inherent weakness in this
type of studies, however, is that neurosphere culture studies only
assess the particular fractions of glioma cells, which are supported
by the neurosphere culture conditions [10], and the neurosphere
culture conditions do not necessarily represent the glioma niche
environment. Additionally, multi-lineage differentiation capacity
can also reflect the differentiation plasticity induced by neuro-
sphere culture conditions. It has been demonstrated that lineage-
restricted progenitors gain multi-lineage differentiation capacity in
neurosphere-forming assay [11,58]. We demonstrate that high-
grade glioma cells, in contrast to low-grade glioma cells, can
express neuronal marker as well as CD133 in vivo. Thus, our data
suggest that the in vivo multi-lineage differentiation capacity is
likely restricted to high-grade glioma cells. It is unclear whether
the in vivo multi-lineage differentiation capacity can be gained
following the progression from low-grade to high-grade gliomas.
Gliomas are composed of a mixture of neoplastic and non-
neoplastic cells [45]. The non-neoplastic cells could include
entrapped neurons, astrocytes, microglial cells, blood vessel cells. It
is also demonstrated inmousegliomamodelsthat normal progenitor
or stem cells can be recruited to glioma niche [45]. Although the
possibility could not be entirely excluded that the cells with normal
karyotype or isolated numerical aberrations are also neoplastic, our
data suggest that most of the entrapped cells in human gliomas show
a progenitor or stem cell-like phenotype and such cells can constitute
more than 40% of the total cells in low-grade gliomas, but their
frequency varies substantially in GBM specimens. It remains to be
established whether neoplastic and non-neoplastic cells in gliomas
can be phenotypically distinguished.
Considering gliomas as a group of progressive tumors, our data
demonstrate that expression of the CD133 associated stem cell
features is correlated with a poor prognosis. High-grade glioma
patients without detectable frequencies of CD133 expressing cells
as well as grade II glioma patients appeared to survive significantly
longer compared to high-grade glioma patients with high
frequencies of CD133 expressing glioma cells. This finding
extends previous studies that ‘‘stem cell-ness’’ gene expression
Table 3. Karyotype analysis of short-term cultured glioma
cells
Patient ID Karyotype
Low-grade glioma
3 normal
4 45,X,-Y[13]/46,XY[10]
high-grade glioma
8 normal
12 45,X,-Y[11]/46,X,-Y,+7[3]/46,XY[10]
13 41-42,X,-Y,der(1)t(1;17)(p36;q21),add(4)(q31),
del(6)(q21),+7,-10,-11,-13, 14,?dup(14)(q12q22),-15,
-17,+2mar,inc[cp9]/80-84,idemx2[cp16]
14 44-45,X,-X,+ider(7)del(7)(q35),-10,-13,del(14)(q22),
del(16)(q21)[cp9]/43,X,-X,der(1)t(1;14)(p34;q22),-4,
der(6)t(6;17)(q23;p11),+ider(7)del(7)(q35),der(8)t(8;9)
(p21;?), idic(9)(?p11;q22),-10,-13, del(16)(q21),
der(17)t(6;17)(?;q11),
der(17)t(13;17)(q12;p13)[cp2
17 45,X,-Y[14]/46,X,-Y,+7[3]/46,XY[6]
18 44,XX,t(9;16)(p23;q12),del(10)(p12),der(12)
t(12;14)(p13;q12),-13,-14,dmin[16]/46,XX[9].
20 90,XX,-Y,-Y,-1,-1,+7,-8,-8,der(14)der(14)t(1;14)(q12;q22)
x2,1-30dmin[cp 3]/45,X,-Y[11]/46,XY[18]
Freshly isolated glioma cells were cultured and analyzed for karyotype between
passage 3 to 4. The number in brackets represents the number of the indicated
karyotype.
doi:10.1371/journal.pone.0001936.t003
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diseases [59,60]. Our findings are consistent with a recent report
on a correlation between enhanced CD133 expression and a poor
clinical outcome in glioma patients [61]. Importantly, we show
that the rare CD133 expressing cells in low-grade gliomas are
predominantly of blood vessel origin. Of note, the frequencies of
CD133 expressing cells in high-grade gliomas analyzed in our
studies appeared to be much higher compared to previous reports
[7,56,61]. This discrepancy could be because we analyzed the
CD133 expressing cells in CD45-negative cell fraction and glioma
specimens can have different contents of hematopoietic cells.
This study constitutes an important step towards clarifying the
lineage commitment and differentiation blockage of glioma cells.
We have demonstrated that normal glial progenitor cell surface
markers are widely expressed in glioma cells. Glial progenitor cell
surface markers could potentially be used to design glial progenitor
antigen-targeted immune therapy or gene therapy. As normal
neural stem cells are believed to be devoid of glial progenitor cell
surface markers, targeted delivery of cytotoxic agents to selectively
ablate glioma cells would spare the normal neural stem cells.
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